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Our objective was to identify the patterns of opioid use among pregnant women enrolled 
in RI Medicaid.  
Methods 
This study used linked RI Medicaid and RI Birth Certificate data from 01/01/2006 to 
12/31/2016. We examined temporal trends of prescription opioid dispensings and 
identified risk factors associated with opioids use during pregnancy.  
Results 
Among 25,500 RI Medicaid enrolled pregnant women who delivered a live baby from 
2008 to 2016, 1,914 (7.5%) received at least one prescription for an opioid medication 
during pregnancy, 810 (3.2%) were during the first trimester, 633 (2.5%) during the 
second trimester, and 866 (3.4%) during the third trimester. Of these, 213 (0.8%) 
women received 3 or more opioids during pregnancy. The prevalence of prescription 
opioids dispensed in pregnant women increased from 4.9% in 2008 to 9.6% in 2015 
(β±SD: 0.66±0.28, P=0.05).  
Conclusions 
Prescription opioid use during pregnancy has increased among women enrolled in RI 
Medicaid.  
 





While gestational opioid use may be associated with increased risk of maternal, fetal, 
and neonatal complications,1,2 there are few studies regarding the opioid use in 
pregnant women. It is important to investigate the extent of opioid use during pregnancy 
to gain insight into the potential risk of maternal opioid exposure on mother and infant 
health. We therefore assessed the use of prescription opioids in a cohort of Medicaid-
enrolled pregnant women in Rhode Island. This population is highly relevant as Rhode 
Island has been disproportionately affected by opioid overuse and addiction as it is 
among the top ten states with the highest rate of opioid overdose deaths.3 In RI the 
number of substance-affected newborns and babies diagnosed with NAS has more than 
doubled from 44/10,000 in 2005 to 94/10,000 in 2016.4 Further, research has shown 
that patients who were opioid abuse or dependence are more likely to be insured thru 
Medicaid than a private insurance company (76.1% vs. 42.8% Nationally).5 With 
covering 30% of the population and 25% of that being women of childbearing age, RI 
Medicaid is an important data source to investigate the impact of the opioid epidemic on 
pregnant women.   
 
The goal of this study was to determine the prevalence of prescription opioid use among 
pregnant women enrolled in the Rhode Island (RI) Medicaid program and to 






Data Source  
This retrospective cohort study evaluated linked RI Medicaid and RI Birth Certificate 
data from January 1, 2006 to December 31, 2016. Deidentified Medicaid medical 
information was provided by RI Executive Office of Human & Health Service (EOHHS). 
These data were comprised of eligibility, medical, and prescription drug records for 
health care services from inpatient hospitals, outpatient clinics, emergency rooms, and 
pharmacies. Demographic information for enrolled members include age, gender, race, 
and location of residency. To validate the pregnancy (exposure) period, we ascertained 
pregnancy outcomes using birth certificate data provided by the RI Department of 
Health (RIDOH), which collects these data within 24 to 48 hours after delivery. The data 
were linked by RI EOHHS and RIDOH then subsequently deidentified for third-party 
research purposes. This study was approved by the Institutional Review Board at the 
RIDOH and University of Rhode Island.  
 
Study Cohort 
We included mothers enrolled in RI Medicaid who had a live birth occurring between 
July 01 2006 to December 31 2016. Mothers who had a diagnosis of cancer pre- or 
post-delivery or were dispensed opioids (methadone or buprenorphine) for Opioid Use 




Gestational age was derived through ultrasound examination of mothers and included in 
RIDOH birth certificate data. The conception date was estimated by subtracting the 
infant’s gestational age, derived through ultrasound examination of mothers. The first 6 
months prior to the conception date was evaluated for baseline opioid utilization. The 
pregnancy window included the period from conception date through delivery date. 
Prescription opioid exposure was evaluated 14 days prior to the conception date 
through delivery date to encompass the possible residual effects of opioid use during 
the conception period. Opioid use was assessed between January 01 2008 and 
December 31 2015 to compare the full year utilization rate.  
 
Prescription Opioid Exposure 
Prescription opioid exposure during pregnancy was obtained through pharmacy records 
using Therapeutic Class Code for filled prescription opioids, and using the number of 
days for which the medication was supplied to determine if exposure occurred during 
the pregnancy window. The prescription opioids considered in this study included 
hydrocodone, oxycodone, codeine, morphine, and tramadol, which were the most 
commonly prescribed opioids for RI Medicaid covered pregnant women.  
 
Opioid exposure was defined as any one receipt of a prescription opioid dispensed 
during the pregnancy exposure window; including opioids dispensed before the 
exposure window with days supply extending to cover at least 1 day within the exposure 
window. Average days of supply and daily doses were calculated. The daily doses for 
each opioid prescription were converted to Morphine Milligram Equilibrium (MME) using 
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the Center for Disease Control (CDC) conversion Table (2016 version). Further 
investigation was conducted to determine the pattern of prescription opioids filled in 
three pregnancy trimesters.  
 
Comparison Group 
To identify the risk factors associated with opioid use during pregnancy, we selected a 




Maternal characteristics at baseline included: age, race, substance use and abuse, 
tobacco use, alcohol use, preexisting conditions, pain conditions, psychiatric 
medications use, and opioid use at baseline. The operational definitions for the medical 
covariates, including substance use and abuse, tobacco use, and alcohol use, are 
described in Appendix Table 1. 
 
Statistical Analyses 
Descriptive analyses of prescription opioid dispensings, temporal trends, and 
corresponding demographic and clinical characteristics were conducted. Continuous 
variables were presented as mean ± standard deviation (SD) and compared using a 
student t test. Categorical variables were presented as frequency (%) and compared 
using a chi-square test or Fisher exact test depending upon the sample size in each 
level. A multivariate logistic regression model was developed to identify significant risk 
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factors associated with opioid use during pregnancy. Statistical significance was set up 
at p≤ 0.05. All statistical analyses were conducted using SAS 9.4 (Cary, NC).  
 
RESULTS 
Of the total included 25,500 pregnancies, 1,914 (7.5%) received a total of 4,046 opioid 
prescriptions at any time during their pregnancy, 810 (3.2%) received a prescription for 
an opioid medication during their first trimester, 633 (2.5%) during their second 
trimester, and 866 (3.4%) during their third trimester. Only 213 (0.8%) pregnancies were 
identified with dispensings of more than 3 prescriptions for opioid medication.  
 
Among those with opioid use during the 6-month period preceding pregnancy, the 
leading documented pain-related indications included: abdominal pain (27%), back pain 
(30%), or headache (18%). Among those with opioid use during the pregnancy period 
the leading documented pain-related indications included: antepartum conditions or 
complications (66%), abdominal pain (38%), back pain (36%), or headache (24%). 
 
Figure 1 shows the temporal trend of prescription opioid use during pregnancy from 
January 01, 2008 to December 31, 2015. The percentage of pregnancies with a 
dispensed opioid increased significantly from 4.9% in 2008 to 11.1% in 2015 (Slope β ± 
SE: 0.9 ± 0.2, p = 0.01), with sharp increases occurring in 2011 (145% from the 
previous year) and 2012 (43% from the previous year).  
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The most commonly dispensed opioids were hydrocodone, oxycodone, codeine, and 
tramadol, respectively (Figure 2). Hydrocodone was the most frequently dispensed 
opioid for all years (39-47% of prescription opioids) except 2008, for which oxycodone 
use was more prevalent (39%).  Four types of opioids (hydrocodone, oxycodone, 
codeine and tramadol) accounted for nearly all prescription opioid use between 2011 - 
2015, while use of other opioid types including morphine and hydromorphone dissipated 
after 2010.  
 
The average days of supply for prescription opioids dispensed was 9.3 days ± 9.4 
(mean±SD). We did not observe a statistically significant trend in change in days supply 
from 2008 to 2015. The average days of supply and MME for four commonly dispensed 
opioids are listed in Table 1. 
 
Demographic and clinical characteristics were assessed during the 6-month baseline 
window and compared between women with and without opioid dispensing during 
pregnancy (Table 2). Women with opioid dispensings during pregnancy were observed 
to be younger (<18: 41% vs 34%, p<.0001), of white race (64% vs 52%, p <.0001), had 
higher rates of tobacco (6.2% vs 2.2%, p<.0001), alcohol (7% vs 1%, p<.001), or 
cocaine use (0.4% vs 0.07%, p<.0001), a higher rate of chronic pain diagnoses (e.g. 
fibromyalgia, migraines and back pain), have more comorbid psychiatric conditions 
(e.g., depression or anxiety), and increased use of psychiatric medications, including 
benzodiazepines, antidepressants, and antipsychotics. 
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Table 3 presents the results of multivariable logistic regression analysis. The significant 
risk factors that were associated with maternal opioid exposure during pregnancy 
included: mother’s age at the delivery (18-24 or 25-34 years old), white race, cocaine 
use, tobacco use, alcohol use, migraine, low back pain, opioid use prior to pregnancy, 
and the year of delivery after 2011. The model fits well (Hosmer and Lemeshow 
Goodness-of-Fit Test: P=0.95) with C Statistics at 0.72. 
 
DISCUSSION 
From 2008 to 2015, approximately 7.5% of RI Medicaid covered women received at 
least one opioid prescription during their pregnancy, and 1 in 4 pregnant women 
received opioid medication for an extended duration, which raises concern given the 
risks of longer-term opioid use in pregnancy. The increased risk for neonatal abstinence 
syndrome or specific cardiovascular and central nervous system defects has been 
reported in previous studies.1,2  
 
Although recent studies showed that opioid use in pregnant women decreased 
from 14.9% in 2005 to 12.9% in 2011 within the US,5,6 we observed an increased 
dispensing of opioids to pregnant women in RI Medicaid that more than doubled from 
5% in 2008 to 11% in 2015, with a sharp rise in 2010 and 2011. The overall increase in 
the dispensing of prescription opioids directly led to an increase in dispensing of 
combination products with hydrocodone, which was dispensed more than all other 
prescription opioids. Based on CDC reports in 2010, approximately 16,651 opioid 
overdose deaths involved oxycodone, hydrocodone, or methadone.3 To control for the 
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dramatic increase in opioid abuse and overdose deaths, the Drug Enforcement 
Administration (DEA) designated hydrocodone combination products from Schedule III 
to a more stringently controlled Schedule II category of drug in 2014.7 However, our 
results showed that hydrocodone was still the most widely dispensed opioid in pregnant 
women on Medicaid in RI in 2014 and 2015.  
 
The opioids most commonly dispensed to RI pregnant women were hydrocodone, 
oxycodone, codeine, and tramadol, respectively. In other studies using national claims 
data, codeine was a more commonly dispensed opioid in pregnant women.6,8 However, 
oxycodone was more widely dispensed to pregnant women in RI than codeine. The 
dispensing rates of hydrocodone and oxycodone almost tripled from 2010 to 2011, and 
increased more than four-fold for codeine. Prescriptions for hydrocodone also increased 
throughout 2011 and 2012, while oxycodone and codeine saw only a relatively small 
increases during this period. After 2012, the dispensing rates for these four commonly 
used opioids appeared to level off.  
 
Previous studies have demonstrated the risk of teratogenesis for some opioids, 
especially when used in the first trimester of pregnancy.1,9 Codeine and hydrocodone 
used early in pregnancy have been associated with greater risk of cardiac septal 
defects, hypoplastic left heart syndrome, spina bifida, and gastroschisis.1 Oxycodone 
has the potential to cause more dependence and overdose. Surprisingly, tramadol, 
classified as a pregnancy category C drug by the FDA due to its potential teratogenic 
effects suggested by animal studies and as a schedule IV drug by the DEA due to its 
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potential for abuse, was also prescribed to pregnant women in RI during the study 
period.  
 
Implications for Practice and/or Policy 
Most pregnant women experience a variety of pain syndromes (e.g. back pain, 
abdominal pain, and migraines) during pregnancy.10 The prevalence of low back or 
pelvic pain was 71.7% in pregnancies,11 while migraines were presented in 35% of 
pregnancies.12 Providers often face difficult choices when prescribing safe and effective 
pain control medications during pregnancy. Non-steroidal anti-inflammatory drugs are a 
poor alternative, as they also pose potential harm to both mother and fetus.13 Careful 
consideration of the potential benefits and harms of perinatal opioid use is of particular 
importance. While opioids are often prescribed they can have adverse effects on the 
fetus.1,2  
 
According to the CDC data, RI has a disproportionately high rate of opioid overdose 
deaths, (N=320, 31.0% in 2017), which is ninth in the nation.3 RI dispensed the highest 
total Morphine Milligram Equivalents (MME) in 2016 (2,623.7 mg/person), more than 
two-fold higher than the average total MME in the US.14 It was also noted that Medicaid 
enrollees have higher rates of prescription opioid use (22%) compared to commercially 
insured patients in the general population (9%).15 Our findings that the rates of opioid 
use significantly increased from 2008 to 2015 confirmed that RI Medicaid-covered 
pregnant women are at a high risk of opioid use. In March 2017 and July 2018, RI 
updated the regulations for Pain Management, Opioid Use, and the Registration of 
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Distributors of Controlled Substances.16 The new version of regulations placed stricter 
controls on prescribing opioids, including dose limits for initial prescriptions. We expect 
to see decreased rates of opioid use in RI in the future.  
 
In some instances the use of opioids for the treatment of pain occurring during 
pregnancy is clinically justifiable. For an opioid prescription to be written and given to a 
patient, it is required that there is a prescriber-patient relationship and ‘medical need’ for 
the medication. In a statement on Opioid Use During Pregnancy, The American College 
of Obstetricians and Gynecologists (ACOG) guided that “Opioids should only be used 
for treatment of pain when alternatives are not appropriate or effective...”17 Yet the 
available literature regarding the safety of opioid use during pregnancy is mixed and 
would be better informed by additional and larger cohort studies. A review of the 
evidence regarding the short-term and long-term risks of opioid use during pregnancy 
reported inconsistent results for studies of fetal development, preterm birth, and birth 
defects overall.18 Many of the studies included in this review involved the use of 
codeine, which was less frequently utilized in our population. The FDA labels for 
oxycodone and hydrocodone note that there are no well-controlled studies in pregnant 
women highlighting an important gap in evidence.19 The new CDC’s guideline for 
prescribing opioids for chronic pain issued in 2016 suggested that physicians prescribe 
non-opioid analgesics or opioids with the lowest dose.20 With the new CDC guideline 
and RI regulation for opioid prescribing,16,20 we expect to see the lower prescribing rate 




Our study has several limitations. First, the use of illicit drugs, including illicit prescription 
opioids, was not captured in this study since the prevalence of illicit drug use is not 
available in the Medicaid claims data. Second, our data source only collects 
prescriptions filled by patients in pharmacies located in RI. Any illicit drug use or opioids 
filled in pharmacies outside of RI are not accounted for. Third, expected opioid use was 
estimated based on pharmacy claims. Actual utilization in patients may deviate from the 
pharmacy dispensing. Fourth, this study is based on the RI Medicaid data. The rates of 
opioid use have substantial geographical variations and are significantly different 
between Medicaid enrollees and commercially insured patients.14,15 Therefore, the study 
findings can only be generalizable to RI Medicaid enrollees. Lastly, this study only 
included women with pregnancies resulting in a live birth. If opioids are associated with 
therapeutic or spontaneous terminations of pregnancies, the total opioid use may be 
underestimated. Nevertheless, Medicaid pharmacy claims data is seen as the gold 
standard of drug exposure compared to outpatient medical records or self-reported drug 
use information. 
 
In conclusion, our findings of increasing rates of prescription opioids, filled by pregnant 
women enrolled in RI Medicaid, calls for a comprehensive safety assessments of 
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Figure 1. Percentage of Pregnancies Dispensed Prescription Opioids for Pain.  





















































Figure 2. Percent of Prescriptions Per Year for Opioid Types Prescribed for Pregnant 






































































Table 1. Morphine Milligram Equivalents (MME) and Supply Days for Opioids 
Prescribed in RI Women.  
Drug Name Average Supply Days 
Median (25th percentile, 75th 
percentile) 
Average MME 
Median (25th percentile, 75th 
percentile) 
Hydrocodone 5 (3, 10) 25 (20, 38) 
Oxycodone 5 (3, 13) 45 (30, 71) 
Codeine 3 (2, 5) 27 (18, 45) 



















Table 2. Comparison of baseline characteristics of pregnant women in RI Medicaid. 
N=25,500. 
Characteristics Exposed to Opioids 
during pregnancy  




N = 23,586 
P Value 
Maternal Age at delivery 
Mean  SD 




















Race, N(%)  
             White 
             Black 






















Tobacco use, N(%) 118 (6.2) 518 (2.2) <.0001 
Alcohol use, N(%) 135 (7) 331 (1.4) <.001 
Maternal preexisting condition, 
N(%) 
              Multiple gestation 
              HIV infection 
              Depression 


























































Table 3. Significant Risk Factors for Maternal Opioid Use during Pregnancy.  
Results of Multivariable Logistic Regression Analysis 





Mother Race White vs Black 1.65 1.32 2.06 <.0001 
 
Cocaine use  3.10 1.15 8.36 0.025 
Tobacco use  1.44 1.12 1.86 0.005 
Alcohol Use 6.38 5.02 8.10 <.0001 
Migraines 1.51 1.22 1.88 0.0002 
Low back pain 1.86 1.52 2.29 <.0001 
Benzodiazepine Use 1.60 1.19 2.14 0.0019 
Opioid use prior to pregnancy 4.40 3.64 5.32 <.0001 
Mother Age < 18 vs 18-24 0.26 0.13 0.54 0.0002 
Mother Age 25-34 vs 18-24 1.45 1.25 1.69 <.0001 
Mother Age ≥ 35 vs 18-24 1.22 0.94 1.59 0.14 
Delivery Year 
2015 vs 2008 
2014 vs 2008 
2013 vs 2008 
2012 vs 2008 
2011 vs 2008 
2010 vs 2008 












































Appendix Table 1. Data Sources and Operational Definitions for Covariates.  
Variables Data Sources Operational Definitions 
Maternal Age RI DOH Birth Certificates Age at delivery 
Race RI DOH Birth Certificates White, Black, and Others 
Marijuana RI Medicaid Inpatient/Outpatient 
Claims 
ICD-9 Diagnosis Code 
Cocaine RI Medicaid Inpatient/Outpatient 
Claims 
ICD-9 Diagnosis Code 
Tobacco use RI Medicaid Inpatient/Outpatient 
Claims 
ICD-9 Diagnosis Code 
Alcohol use RI Medicaid Inpatient/Outpatient 
Claims 
ICD-9 Diagnosis Code 
Multiple gestation RI DOH Birth Certificates  
HIV infection RI Medicaid Inpatient/Outpatient 
Claims 
ICD-9 Diagnosis Code 
Depression RI Medicaid Inpatient/Outpatient 
Claims 
ICD-9 Diagnosis Code 
Anxiety RI Medicaid Inpatient/Outpatient 
Claims 
ICD-9 Diagnosis Code 
Fibromyalgia RI Medicaid Inpatient/Outpatient 
Claims 
ICD-9 Diagnosis Code 
Migraine RI Medicaid Inpatient/Outpatient 
Claims 
ICD-9 Diagnosis Code 
Back pain RI Medicaid Inpatient/Outpatient 
Claims 
ICD-9 Diagnosis Code 
Anxiolytics Use RI Medicaid Pharmacy Claims Therapeutic Class Code 
Antidepressants Use RI Medicaid Pharmacy Claims Therapeutic Class Code 
Antipsychotics Use RI Medicaid Pharmacy Claims Therapeutic Class Code 
Stimulants Use RI Medicaid Pharmacy Claims Therapeutic Class Code 
Opioid use at baseline RI Medicaid Pharmacy Claims Therapeutic Class Code 
 
 
 
 
 
 
 
 
